Owlstone Medical, the UK-based developer of “breath biomarkers” for various medical diagnostics purposes, has won a contract from the US Department of Defense that will put a lightweight, portable version of its technology on the battlefield.
Under a new agreement, Owlstone and the DoD’s Innovation Unit will work on Exhale, a project that intends to develop a handheld device for non-invasive detection of pre-symptomatic respiratory infectious...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?